Kezar Life Sciences (NASDAQ:KZR) Given “Market Perform” Rating at William Blair

William Blair reiterated their market perform rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a report released on Wednesday morning,RTT News reports.

Separately, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th.

Kezar Life Sciences Price Performance

Shares of Kezar Life Sciences stock traded up $0.05 during midday trading on Wednesday, reaching $7.54. The company had a trading volume of 35,765 shares, compared to its average volume of 74,179. The stock has a fifty day simple moving average of $7.13 and a 200 day simple moving average of $6.84. The company has a market capitalization of $55.01 million, a price-to-earnings ratio of -0.57 and a beta of 0.22. Kezar Life Sciences has a 1-year low of $5.20 and a 1-year high of $11.35. The company has a current ratio of 9.58, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($2.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.20) by $0.40. As a group, equities research analysts forecast that Kezar Life Sciences will post -11.95 earnings per share for the current year.

Hedge Funds Weigh In On Kezar Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in KZR. Mackenzie Financial Corp purchased a new stake in Kezar Life Sciences during the second quarter valued at $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Kezar Life Sciences during the second quarter valued at approximately $63,000. BNP Paribas Financial Markets raised its position in Kezar Life Sciences by 35.4% in the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after acquiring an additional 71,543 shares during the period. Ikarian Capital LLC boosted its stake in shares of Kezar Life Sciences by 1.8% during the 1st quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock worth $783,000 after acquiring an additional 15,601 shares during the last quarter. Finally, Acuitas Investments LLC grew its position in shares of Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after acquiring an additional 295,956 shares during the period. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.